COST-EFECTIVENESS ANALYSIS OF DOCETAXEL VS DOCETAXEL plus TRASTUZUMAB AS FIRST LINE THERAPY IN THE TREATMENT OF PATIENTS WITH METATSTASTIC BREAST CANCER HER2/NEU+

被引：0
|
作者：
Tenorio, C. [1 ]
Vargas, J. [2 ]
Martinez, J. [3 ]
Paladio, A. [2 ]
机构：
[1] Inst Nacl Cancerol, Mexico City, DF, Mexico
[2] Econopharma Consulting SA CV, Mexico City, DF, Mexico
[3] Econopharma, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74343-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A274 / A274
页数：1
相关论文
共 50 条
  • [1] Sunitinib plus docetaxel and trastuzumab as first-line therapy for HER2+advanced breast cancer
    Cardoso, F.
    Canon, J. L.
    Amadori, D.
    Dirix, L.
    Villa, E.
    Aldrighetti, D.
    Machiels, J. P.
    Verkh, L.
    Kern, K.
    Giorgetti, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 283 - 283
  • [2] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB plus DOCETAXEL VERSUS DOCETAXEL ALONE IN THE TREATMENT OF HER2+METASTATIC BREAST CANCER
    Athanasakis, K.
    Golna, C.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A449
  • [3] ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB plus DOCETAXEL FOR TREATMENT OF PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER AGAINST TREATMENT WITH TRASTUZUMAB plus DOCETAXEL plus PLACEBO, IN THE VENEZUELAN CONTEXT
    Romero, M.
    Huerfano, L. M.
    Acero, G.
    VALUE IN HEALTH, 2015, 18 (07) : A822 - A822
  • [4] Randomized phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer
    Najagami, K.
    Inoue, K.
    Mizutani, M.
    Hozumi, Y.
    Fujiwara, Y.
    Masuda, N.
    Tsukamoto, F.
    Saito, M.
    Ohashi, Y.
    Sano, M.
    Noguchi, S.
    CANCER RESEARCH, 2009, 69 (02) : 241S - 242S
  • [5] Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast Cancer
    Susanne Taucher
    Margaretha Rudas
    Robert M. Mader
    Michael Gnant
    Emanuel Sporn
    Peter Dubsky
    Sebastian Roka
    Thomas Bachleitner
    Florian Fitzal
    Daniela Kandioler
    Catharina Wenzel
    Günther G. Steger
    Martina Mittlböck
    Raimund Jakesz
    Breast Cancer Research and Treatment, 2003, 82 : 207 - 213
  • [6] Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer
    Taucher, S
    Rudas, M
    Mader, RM
    Gnant, M
    Sporn, E
    Dubsky, P
    Roka, S
    Bachleitner, T
    Fitzal, F
    Kandioler, D
    Wenzel, C
    Steger, GG
    Mittlböck, M
    Jakesz, R
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 (03) : 207 - 213
  • [7] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
    Giampaolo Bianchini
    Astrid Kiermaier
    Giulia Valeria Bianchi
    Young-Hyuck Im
    Tadeusz Pienkowski
    Mei-Ching Liu
    Ling-Ming Tseng
    Mitch Dowsett
    Lila Zabaglo
    Sarah Kirk
    Tania Szado
    Jennifer Eng-Wong
    Lukas C. Amler
    Pinuccia Valagussa
    Luca Gianni
    Breast Cancer Research, 19
  • [8] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
    Bianchini, Giampaolo
    Kiermaier, Astrid
    Bianchi, Giulia Valeria
    Im, Young-Hyuck
    Pienkowski, Tadeusz
    Liu, Mei-Ching
    Tseng, Ling-Ming
    Dowsett, Mitch
    Zabaglo, Lila
    Kirk, Sarah
    Szado, Tania
    Eng-Wong, Jennifer
    Amler, Lukas C.
    Valagussa, Pinuccia
    Gianni, Luca
    BREAST CANCER RESEARCH, 2017, 19
  • [9] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
    Wardley, Andrew M.
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis M.
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Barton, Claire
    Button, Peter
    Hersberger, Veronica
    Torres, Antonio Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
  • [10] BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)
    Pienkowski, Tadeusz
    Forbes, John
    Valero, Vicente
    Eiermann, Wolfgang
    Von Minckwitz, Gunter
    Martin, Miguel
    Smylie, Michael
    Crown, John
    Noel, Nathalie
    Pegram, Mark
    ANNALS OF ONCOLOGY, 2006, 17 : 71 - 71
12345